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Abstract
Background: Autoreactive B cells are crucial players in the pathogenesis of rheumatoid arthritis (RA). Autoantibodies
specific for citrullinated proteins (ACPA), present in the serum of approximately 60–70 % of patients, have a pathogenic
role in the disease. B cell depleting therapies may result in a transient immunosuppression, increasing the risk of
infections. Our aim was to develop a new therapeutic approach to selectively deplete the ACPA producing
autoreactive B cells.
Methods: To target B cells synthetic citrullinated peptide derived from the β chain of fibrin, β60-74Cit 60,72,74
(β60-74Cit), the predominant epitope recognized by ACPA was used. Complement dependent cytotoxicity (CDC) was
induced by a modified peptide derived from gp120 of HIV-1. To trigger CDC both the targeting peptide and the
complement activating peptide were covalently coupled in multiple copies to the surface of poly (DL-lactic-co-glycolic
acid) nanoparticles (NPs). Ex vivo antibody synthesis was examined by ELISA and ELISpot. CDC was tested after dead
cell staining by flow cytometry.
Results: The β60-74Cit peptide was selectively recognized by a small subset of B cells from RA patients having high
level of peptide specific serum antibody, suggesting that the peptide can target diseased B cells. The modified gp120
peptide covalently coupled to NPs induced the formation of the complement membrane attack complex, C5b-9 in
human serum. We show here for the first time that bifunctional NPs coupled to multiple copies of both the targeting
peptide and the complement activating effector peptide on their surface significantly reduce β60-74Cit peptide
specific ex vivo ACPA production, by inducing complement dependent lysis of the citrullinated peptide specific B cells
of seropositive RA patients.
Conclusions: Bifunctional NPs covalently coupled to autoantigen epitope peptide and to a lytic peptide activating
complement may specifically target and deplete the peptide specific autoreactive B-cells.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory auto-
immune disease affecting mainly the small joints of the
hands and feet causing severe tissue injury [1, 2]. RA has a
worldwide distribution with an estimated prevalence of
0.5–0.75 %. Anti-citrullinated protein antibodies (ACPA)
are present in approximately 60–70 % of RA patients.
Citrullination is a posttranscriptional modification of
arginine in certain proteins induced by peptidyl arginine-
deiminase enzymes [3]. ACPA sometimes appear long
before the manifestation of the disease [4], and therefore
detection is not only the most specific and sensitive
current diagnostic tool for RA [5] but also proved to have
pathogenic significance. Several target proteins for ACPA
have been described, such as citrullinated filaggrin [6–9],
fibrin [10–13], vimentin [14–17], enolase [18–20], colla-
gen [21–24], and certain viral proteins [25–27]. ACPA in
the inflamed synovium have been shown to associate with
citrullinated protein antigens such as fibrin to form im-
mune complexes, leading to the progression of the inflam-
matory process [28, 29].
One of the most effective biological disease-modifying
anti-rheumatic drugs is rituximab, a human CD20-
specific chimeric monoclonal antibody, depleting CD20-
bearing B cells [30–32]. After rituximab treatment, the
B-cell number falls to an almost undetectable level at
3 months in most of the patients, and starts to rise at
about 6 months [33]. Monitoring of serum antibody
levels in rituximab-treated patients revealed that while
titers of rheumatoid factor (RF) and anti-CCP antibodies
significantly dropped, the humoral immune response to-
wards most pathogens remained unaffected [34]. How-
ever, the transient absence of B cells may lead to an
immunosuppressed state and leave the patients less pro-
tected against infections [35, 36].
Depletion of autoantigen-specific B-cell subsets recog-
nizing the citrullinated protein epitopes might therefore
be a more favorable therapeutic option. Citrulline (Cit)-
containing peptides corresponding to ACPA epitopes
may be recognized by circulating autoreactive B cells.
We and others have shown that B cells from RA patients
produce citrullinated epitope-specific antibodies ex vivo
[37–40]. These data prompted us to introduce a Cit-
containing peptide as a recognition unit to target specif-
ically the autoreactive B cells.
The predominant synovial target for ACPA is the
citrullinated fibrin [11–13]. Based on previous results
identifying fibrin β60-74Cit60,72,74 (β60-74Cit) as the
major epitope, we selected the corresponding synthetic
peptide 60XPAPPPISGGGYXAX74 (X = Cit) for further
experiments [10–12].
Complement-dependent lysis is one of the depletion
mechanisms of B cells by rituximab, the most frequently
applied B-cell depleting antibody [41, 42]. Therefore, we
postulated that β60-74Cit peptide combined with a poten-
tially complement activating peptide would induce specific
lysis of the targeted epitope-specific B cells. Süsal et al. re-
ported the complement activating capacity of a synthetic
peptide derived from gp120 of human immunodeficiency
virus type 1 (HIV-1) [43]. Based on this finding, we syn-
thesized a novel peptide, Ac-233C(Acm)NNQTFNGTGP-
C(Acm)TNV247-K-NH2 (CNNQK), and then coupled it
together with the targeting β60-74Cit peptide to the
surface of carboxylate functionalized copolymer poly(D,L-
lactic-co-glycolic acid) (PLGA) nanoparticles (NPs).
The results shown here revealed that these bifunc-
tional NPs significantly reduced ACPA production in ex
vivo culture by inducing complement-dependent lysis of
citrullinated fibrin β-specific B cells.
Methods
Patients
For this cross-sectional study, blood samples were collected
from 170 RA patients (146 women/24 men; median age
63 years, interquartile range 51–70; median disease
duration 6 years, interquartile range 3–13) with established
disease at the Buda Hospital, Budapest, Hungary of
Hospitaller Brothers of St John. The diagnosis of the disease
was established on the basis of the revised classification cri-
teria of the American College of Rheumatology (ACR)/
European League against Rheumatism (EULAR) [44].
Blood samples were taken with ethical permission and
after the patients signed a written consent. The study has
been approved by National Public Health and Medical
Officer Service. Selected patients with a high level of β60-
74Cit specific autoantibody (enzyme-linked immunosorb-
ent assay (ELISA) ratios between 5 and 21 for β60-74Cit)
were repeatedly recruited for the functional assays
(Table 1). A total of 138 age-matched healthy control sera
were obtained from the 3rd Department of Medicine,
Semmelweis University, Budapest, Hungary.
Peptide synthesis
All peptides were synthesized by solid-phase peptide
synthesis as described previously [11, 38, 45]. The N-
terminus of peptides was free or acetylated. N-terminally
labeled β60-74 peptide amides (both β60-74Cit and β60-
74Arg) were synthesized using biotinyl-aminohexanoic
acid [38, 45]. The –COOH group on the C-terminus
was always amidated (Table 2). Peptides were purified by
semipreparative reversed-phase high-performance liquid
chromatography (HPLC) and were characterized by ana-
lytical reversed-phase HPLC and electrospray ionization
mass spectrometry (ESI-MS).
Preparation and characterization of bifunctional PLGA NPs
Carboxylate-functionalized PLGA NPs were prepared by
the nanoprecipitation method [46, 47]. The average
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hydrodynamic diameter, polydispersity, and zeta potential
of PLGA NPs were characterized by dynamic light scatter-
ing and zeta potential measurements. The NPs were dis-
persed in doubly distilled water, finally containing 1.6 ×
1011 NPs/ml. The average diameter of NPs was 160–
180 nm, and each NP contained approximately 4–5000
carboxyl groups available for covalent binding of peptides.
NPs were converted in Milli-Q, Merck KGaA, Darmstadt,
Germany water to PLGA-active ester derivative with high
excess N-hydroxysuccinimide and 1-ethyl-3-(3-dimethyla-
minopropyl)-carbodiimide. The N-hydroxysuccinimide-ac-
tivated particles were covalently linked to a 1:1 (mol:mol)
mixture of CNNQK and β60-74Cit peptides. It should be
noted that the targeting β60-74Cit peptide was coupled at
its N-terminal α-amino group, while the CNNQK peptide
was coupled at its C-terminal ε-amino group of Lys residue
to the NPs. This attachment strategy resulted in uniformly
oriented peptides of the two types. The efficient coupling of
Table 1 Clinical data of rheumatoid arthritis patients used in functional assays
Gender Age (years) Disease duration
(years)
CRP (mg/l) RF (IU/ml) ACPA (IU/ml) DAS28 ESR (mm/h) Treatment β60-74
ELISA ratio
Patient 1 Female 54 5 8.1 264 1971 4.99 15 Sal, Afl, Lefl 10.26
Patient 2 Female 55 6 8.2 265 1971 4.1 16 Sal, Afl, Lefl 11.26
Patient 3 Female 78 9 1.84 16.2 2410 3.7 10 MTX 15.26
Patient 4 Female 82 12 2.1 10.9 Neg. 5.05 47 MTX, Med 0.89
Patient 5 Female 62 8 0.41 293.6 2403 2.17 21 Trexan 0.94
Patient 6 Male 45 6 0.7 47 3200 0.63 2 Del, Trexan 0.74
Patient 7 Female 52 4 3.1 264.1 3200 4.09 29 MTX, Med 6.59
Patient 8 Female 71 7 2.3 15 1759 2.83 19 MTX, Med 7.41
Patient 9 Female 39 6 0.5 96.2 3073 2.06 3 MTX 14.81
Patient 10 Female 45 3 1.9 394.5 295 1.1 3 MTX, Med 9.97
Patient 11 Female 43 3 2.5 10.3 952 1.05 6 Imuran, Metoject 7.65
Patient 12 Male 75 12 37.8 51.5 3200 2.5 4 Med, MTX 6.55
Patient 13 Male 74 19 0.14 360.9 2403 0.84 5 Roactemrat 13.8
Patient 14 Female 45 5 4.64 74.4 2991 4.01 9 Medrol, Trexan 20.97
Patient 15 Female 64 7 3.1 15.6 951 2.22 13 Lefl, Med 3.58
Patient 16 Female 63 5 6.7 673 964 2.1 20 Sal, Metoject 9.56
Patient 17 Male 70 9 9.3 25 3200 2.63 5 MTX, Sal, Med 14.35
Patient 18 Female 76 24 19.7 225 2132 7.97 42 Med, MTX 8.31
Patient 19 Female 41 1 2.3 129 765 3.41 4 Med 6.98
Patient 20 Female 60 9 47.86 65.3 349 5.39 97 Med, Nebivolol 6.35
ACPA anti-citrullinated protein antibodies, Afl aflamin, CRP C-reactive protein, DAS28 Disease Activity Score of 28 joints, Del delagil, ELISA enzyme-linked immunosorbent
assay, ESR erythrocyte sedimentation rate, Lefl leflunomid, Med medrol, MTX methotrexate, Neg negative, RF rheumatoid factor, Sal salazopyrin
Table 2 Sequences of peptides used for the ELISA experiments and for the bifunctional nanoconstructs





HIV-1 gp120233–247 Complement activating peptide CNNK Ac-
233C(Acm)NNKTFNGTGPC(Acm)TNV247-NH2
HIV-1 gp120233–247 Q-substituted complement activating peptide CNNQ Ac-
233C(Acm)NNQTFNGTGPC(Acm)TNV247-NH2
HIV-1 gp120233–247 Q-substituted complement activating peptide with C-terminal K CNNQK Ac-
233C(Acm)NNQTFNGTGPC(Acm)TNV247-K-NH2
aStandard one-letter code for amino acid residues: X citrulline, Ac– acetyl group, –NH2 amid group, Acm acetamidomethyl group, Biot
biotinyl-aminohexanoyl group
ELISA enzyme-linked immunosorbent assay, HIV-1 human immunodeficiency virus type 1
Bold letters stand for modified amino acids that are not present in the natural sequences
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peptides to NPs was controlled after enzymatic digestion by
HPLC/mass spectrometry (data not shown).
B-cell purification
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from healthy donors and RA patients as described
previously [38]. For the peptide-specific antibody secre-
tion assay, B cells were purified by negative selection
using RosetteSep antibody cocktail (Stem Cell Technolo-
gies, Vancouver, BC, Canada), according to the manufac-
turer’s instructions. The purity of the resulting B-cell
population was 80–85 %. To stimulate antibody secretion,
106 B cells/ml were cultured for 5 days in the presence of
7.5 μg/ml phosphorothioated unmethylated CpG oli-
godeoxynucleotide (ODN-2006, 5′-tcgtcgttttgtcgttttg
tcgt′-3′; Sigma Aldrich Co., St. Louis, MO, USA) and
1.5 ng/ml human recombinant B-cell activating factor
of the tumor necrosis family (BAFF; ImmunoTools
GmbH, Friesoythe, Germany). The combined stimuli
with CpG and BAFF were applied since Toll-like re-
ceptor TLR9 activation by CpG renders human B
cells more sensitive to the effects of BAFF by increas-
ing the membrane-bound BAFF that may enhance B-
cell proliferation, differentiation, and autoantibody
production [48].
A higher purity of B cells is needed for the peptide-
binding and for the cytotoxicity assays. B cells were
therefore purified by negative selection using magnetic
bead-activated cell sorting (MACS) according to the man-
ufacturer’s protocol (Miltenyi Biotec, Auburn, CA, USA).
The purity of the resulting B-cell population was 85–98 %.
B cells (106/ml) were cultured with 1 μg/ml CpG, 50 ng/
ml interleukin (IL)-2, and 50 ng/ml IL-21 (ImmunoTools
GmbH) for 48 hours to increase the frequency of activated
memory B cells.
ELISA
In the serum ELISA, N-terminally biotinylated β60-
74Cit and β60-74Arg were used. Biotinylated peptides
(1 μg/ml in phosphate-buffered saline (PBS)) were
bound to a NeutrAvidin (5 μg/ml in PBS; Pierce Bio-
technology, Rockford, IL, USA) precoated plate [45].
ELISA ratios were calculated (optical density (OD) with
β60-74Cit/OD with β60-74Arg) and compared between
groups. The cutoff value was calculated from ELISA ratios
of 138 healthy samples (means of ELISA ratios ± 2*standard
deviation (SD)).
Antibody secretion was determined by ELISA from the
supernatant of in vitro stimulated B cells, with plates
coated as already described. The peptide-specific
antibodies were detected by horseradish peroxidase
(HRP)-conjugated anti-human IgG +M (Jackson Immu-
noresearch Laboratories Inc., West Grove, PA, USA).
Detection of β60-74Cit peptide-specific B cells by flow
cytometry
Purified B cells were cultured with 1 μg/ml CpG and
10 ng/ml IL-2 for 48 hours to increase the frequency of
memory B cells. The biotinylated β60-74Cit or β60-74Arg
peptides were coupled to NeutrAvidin-labeled yellow–green
microspheres (1 μm diameter; Thermo Fisher Scientific
Inc., Waltham, MA, USA). The peptide-coated fluorescent
microspheres were added to B cells at 100-fold excess and
the samples were incubated for 1 hour at 4 °C. The
peptide-specific B cells were detected with a FACSCalibur
flow cytometer (Becton-Dickinson, Franklin Lakes, NJ,
USA) and data were analyzed using FlowJo software (Tree
Star Inc., Ashland, OR, USA).
Detection of IgG secreting cells by enzyme-linked
immunospot assay
PBMCs were cultured in RPMI-1640 containing 10 %
fetal calf serum in the presence of 10 ng/ml recombinant
IL-2 and 1 μg/ml R848 polyclonal activator provided
with the enzyme-linked immunospot assay (ELISpot) kit
(Mabtech, Stockholm, Sweden). The cells were harvested
at the 3rd day, and incubated for 1 hour with the bifunc-
tional PLGA NPs at 1000-fold excess. After removing
the unbound NPs, the cells were incubated at 37 °C for
30 minutes in the presence of 1 %, 3 %, 5 % and 10 %
pooled normal human serum (NHS) as a complement
source or in heat-inactivated serum. After washing, 4 ×
105 PBMCs were transferred into the wells of ELISpot
plates precoated with the β60-74Cit peptides and with
anti-IgG, respectively. The spots were developed after
18 hours by biotinylated detection monoclonal anti-
bodies, streptavidin HRP, and substrate (Mabtech). The fre-
quency of IgG-specific and peptide-specific IgG-producing
cells was determined using a C.T.L. Immunospot analyzer
(CTL-Europe GmbH, Bonn, Germany).
Measuring the complement activating capacity of the
modified HIV-1 gp120 peptides
Complement activation by the modified gp120 pep-
tides 233C(Acm)NNKTFNGTGPC(Acm)TN247 (CNNK)
and 233C(Acm)NNQTFNGTGPC(Acm)TNV247 (CNNQ)
(Table 2) was tested by ELISA. High-binding ELISA plates
(Greiner bio-one GmbH, Frickenhausen, Germany) were
coated with 10 μg/ml peptide or with 100 μg/ml IgG as a
control. Pooled human serum or heat-inactivated serum
was added at 1:50 dilution for 1 hour. The deposited com-
plement C3 cleavage products were detected by HRP-
conjugated anti-human-C3 (MP Biomedicals, Solon, OH,
USA), while C4 and C9 were detected by anti-human C4
and C9 antibodies (Merck KGaA, Darmstadt, Germany),
respectively, followed by HRP-conjugated anti-goat IgG.
The C1q depleted serum and the C3-depleted serum was
purchased from Merck KGaA.
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To test the complement activating capacity of the
CNNQK-coated and β60-74Cit-coated bifunctional NPs,
the release of the soluble complement components
(SC5b-9) was measured. Then 109 NPs were incubated
in 100 μl 50 % human serum for 1 hour at 37 °C and
SC5b-9 was determined in the supernatant by the SC5b-
9 Plus kit (Quidel, San Diego, CA, USA) according to
the manufacturer’s instruction.
Cytotoxicity assay
B cells (106 B cells/ml) were prestimulated with 1 μg/ml
CpG and 10 ng/ml IL-2 for 48 hours. The bifunctional,
fluorescein-containing NPs covered with the targeting
β60-74Cit and the effector CNNQK peptides were added
to B cells at 5000-fold excess, and then the samples were
incubated for 1 hour on ice. After washing, the cells
were incubated with 20 % pooled human serum as a
complement source or heat-inactivated serum for 30 mi-
nutes at 37 °C, and then were stained with TO-PRO®-3
(Thermo Fisher Scientific Inc.) for 15 minutes to detect
damaged cells. The dead β60-74Cit peptide-specific B
cells were detected as the FL1/FL4 double-positive
population with a FACSCalibur flow cytometer (Becton-
Dickinson), and data were analyzed using FlowJo soft-
ware (Tree Star Inc.).
Statistical analysis
For the statistical analysis of data, the Mann–Whitney
test (Fig. 1a), analysis of variance (ANOVA) (Figs. 1c, 2
and 3a, b, d) and the two-tailed t test (Figs. 3c, 4 and 5)
were used and the results were analyzed with GRAPHPAD
PRISM 4 software (GraphPad Software, La Jolla, CA, USA).
In all tests, p <0.05 was considered significant.
Results
Recognition of Cit-containing fibrin β peptide by serum
antibodies and by B cells of RA patients
Sera samples of 170 diagnosed RA patients and 138 healthy
blood donors were screened by indirect ELISA. The ELISA
ratios and the receiver operating characteristic curve are
shown in Fig. 1a and b, respectively. With our experimental
set up, at a 95 % specificity level β60-74Cit peptide was rec-
ognized by serum antibodies from 52 % of RA patients.
The presence of the serum antibodies specific for β60-
74Cit suggests that we should find memory B cells in the
blood of RA patients with identical specificity. To increase
the binding avidity of the peptide we applied neutravidin-
labeled polystyrene microspheres (1 μm diameter) loaded
with a high-intensity fluorescent dye, coating its surface
with Biot-β60-74Cit or Biot-β60-74Arg. B cells from se-
lected anti-β60-74Cit peptide-positive or peptide-negative
RA patients and from healthy controls were prestimulated
to increase the frequency of memory B cells [49]. Micro-
spheres coated with β60-74Arg bound to B cells at the
same level as the uncoated controls, while microspheres
covered with the β60-74Cit peptide specifically bound to a
small but significant proportion of B cells from RA pa-
tients, but not to B cells from healthy volunteers, or from
β60-74Cit antibody-negative patients (Fig. 1c).
In vitro secretion of β60-74Cit peptide-specific antibodies
by B cells of RA patients
To reveal whether ex vivo stimulation of B cells results
in β60-74Cit peptide-specific antibody secretion, purified
B cells from selected RA patients with high serum anti-
body level and from healthy controls were cultured for
5 days in the presence of the TLR9 agonist, CpG ODN,




































































Fig. 1 Recognition of Cit-containing peptide epitope of fibrin β chain by antibodies in sera of RA patients and healthy blood donors a, b and by
isolated B cells c. a Reactivities of RA (n = 170) or healthy (n = 138) serum samples with N-terminally bitotinylated β60-74Cit vs. β60-74Arg bound
to neutravidin precoated plates. ELISA ratios were calculated (OD with β60-74Cit /OD with β60-74Arg). Data were analyzed with the Mann–Whitney
test, and the median OD ratio of RA samples was 1.68, interquartile range 0.95–6.33, and the median OD ratio of healthy samples was 0.91, interquartile
range 0.81–1.07 (***p <0.001). b Receiver operating characteristic curve analysis, area under the curve value for β60-74Cit: 0.7661. c Binding of
β60-74Cit and β60-74Arg-coated fluorescent microspheres to prestimulated B cells from β60-74Cit seropositive or seronegative RA patients and from
healthy individuals (n = 3/group, ELISA ratios of the selected β60-74Cit seropositive RA patients were between 10 and 15). Bars show means ± SD,
*p <0.05. OD optical density, RA rheumatoid arthritis, H healthy
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and BAFF. Antibody production was followed by testing
the presence of native β60-74Arg-specific and β60-
74Cit-specific IgG in the culture supernatants. B cells
from healthy individuals did not produce a considerable
amount of peptide-specific antibodies, while the patients’
B cells secreted IgG specific for the β60-74Cit peptide
even without stimulation. A significantly lower level of
β60-74Arg specific IgG was detected in all samples. CpG
and BAFF double stimuli increased the β60-74Cit















































































































Fig. 2 β60-74Cit peptide-specific antibody secretion of purified B cells from healthy donors and RA patients. B cells were cultured for 5 days in
the presence or absence of 7.5 μg/ml CpG and 1.5 ng/ml BAFF a Antibody reactivities in the supernatants against β60-74Cit (filled symbols) and
β60-74Arg (open symbols) peptides were detected by ELISA. Individual data points of unstimulated b and stimulated c samples are shown. The
ELISA ratios of serum samples from the same donors were between 6 and 14. n healthy = 3, nRA = 5. The data were analyzed with the paired t test,
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Fig. 3 Complement activating capacities of HIV-1 gp120 derivative peptides CNNK and CNNQ and the NP-coupled CNNQK. a Pooled normal
human sera (NHS) or inactivated sera were added to peptide-coated or IgG-coated plates. The deposited complement components C3, C4, and
C9 were detected by anti-human C3-HRP, and anti-human C4 and C9 followed by HRP-conjugated anti-goat IgG, respectively. b C3 deposition
from NHS is compared with that of C3 or C1q depleted serum and from NHS inactivated with heat or EDTA. c Comparison of C3 deposition
induced by CNNK and the modified CNNQ peptide, and by human IgG. d CNNQK and β60-74Cit peptide-coupled NPs activate the C5b-9 terminal
complex formation in human serum. Statistics: a, b, d analyzed with ANOVA, c analyzed with paired t test, means ± SD are shown (*p <0.05,
**p <0.01, ***p <0.001). EDTA ethylenediamine tetraacetic acid, OD optical density, PLGA poly(D,L-lactic-co-glycolic acid), RA rheumatoid arthritis
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sets are shown in Fig. 2b (unstimulated cells) and Fig. 2c
(B cells stimulated with CpG and BAFF).
Analysis of complement activating capacity of the
modified gp120-derived synthetic peptides and the
bifunctional NPs
In order to induce complement-dependent lysis of auto-
reactive B cells, our aim was to combine the targeting
properties of β60-74Cit peptide with a peptide inducing
complement activation. We shortened the corresponding
gp120 peptide [43] at the C-terminal end with protected
Cys residues and obtained the peptide CNNK (Table 2).
CNNK had a comparable complement activating prop-
erty with IgG regarding C3 and C4 deposition, while a
somewhat lower level of C9 deposition was detected that
was still significantly higher as compared with heat-
inactivated sera (Fig. 3a).
C1q is essential to trigger the classical complement ac-
tivation pathway. Neither the CNNK peptide nor IgG in-
duced deposition of C3 from C1q-depleted as well as
from C3-depleted sera, indicating that the classical path-
way is activated. EDTA by chelating Ca2+ inhibited com-
plement activation, and thereby C3 deposition (Fig. 3b).
For the coupling of CNNK peptide to the surface of NPs
first we had to substitute 236Lys with Gln. The new pep-
tide CNNQ had identical reactivity with CNNK, both in-
ducing C3 deposition on peptide-coated surfaces (Fig. 3c).
CNNQ peptide was coupled to NPs via the ε amino
group of an added C-terminal Lys (CNNQK). The com-
plement activation property of the bifunctional NPs



















































































































































Fig. 4 β60-74Cit and CNNQK peptide-coated bifunctional NPs suppress ex vivo synthesis of β60-74Cit specific antibodies in the presence of active
complement in human sera. a PBMCs from RA patients (n = 17, ELISA ratios for β60-74Cit between 6 and 21) and b from healthy donors (n = 5)
were stimulated with the TLR7/TLR8 agonist, R848, and IL-2 for 72 hours, and then the bifunctional NPs were added to the harvested cells
followed by normal human sera (NHS) or heat-inactivated NHS (iNHS) at different concentrations. The number of β60-74Cit-specific IgG-producing
plasma cells was counted by ELISPot. c Individual data of RA patients at 10 % iNHS and NHS are shown. d Representative ELISpot images.
Statistics: a, c analyzed with paired t test, means ± SD are shown (**p <0.01, ***p <0.001). ACPA anti-citrullinated protein antibody, PBMC peripheral
blood mononuclear cell, RA rheumatoid arthritis, H healthy
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peptides was tested by monitoring the formation of sol-
uble C5b-9 terminal complex in human serum (Fig. 3d).
Bifunctional NPs induced a significantly higher C5b-9
release as compared with noncoated NPs, indicating that
the former activate the terminal components of comple-
ment system.
β60-74Cit and CNNQK peptide-coated bifunctional NPs
suppress β60-74Cit-specific antibody synthesis
To study whether bifunctional NPs indeed target B cells
that specifically recognize the β60-74Cit peptide, PBMCs
from selected RA patients having high β60-74Cit
peptide-specific serum antibody level and from healthy
donors were stimulated with the TLR7/TLR8 agonist,
R848, and IL-2 for 72 hours, and then the harvested cells
were incubated with the bifunctional NPs, followed by
the addition of pooled human sera or inactivated sera at
different concentrations. The number of peptide-specific
IgG-producing plasma cells was estimated by ELISpot
on the next day. Stimulation of B cells from RA patients
but not from healthy individuals by TLR-mediated sig-































FL-1: Fluorescein-loaded plga nanobeads























Fig. 5 Complement-dependent lysis of β60-74Cit peptide-specific B cells induced by bifunctional PLGA NPs in the presence of NHS as measured
by flow cytometry. a Upper panel: representative figure of a healthy donor, lower panel: typical result with an RA patient. The binding of
fluorescein-loaded NPs was detected in channel 1, dead cells were detected after TO-PRO staining in channel 4. The β60-74Cit-positive, killed B
cells are detected in the right upper quadrant of the dot plot. b Individual data of five RA patients. ELISA ratios of sera of the same RA patients
were between 5 and 19. Data were analyzed with paired t test, means ± SD are shown (**p <0.01). iNHS heat-inactivated normal human sera, NHS
normal human sera, PLGA poly(D,L-lactic-co-glycolic acid)
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secreted β60-74Cit peptide-specific antibodies (Fig. 4a,
b). In the presence of active complement, depending on
serum concentration, the bifunctional NPs significantly
reduced the number of β60-74Cit peptide-specific
plasma cells, while in heat-inactivated serum NPs had
no effect (Fig. 4a). The individual peptide-specific spot
numbers in samples treated with 10 % heat-inactivated
or active sera (Fig. 4c) and representative ELISpot im-
ages (Fig. 4d) are shown. Nonspecific IgG secretion was
not affected by the bifunctional NPs (data not shown).
The bifunctional NPs induce complement-dependent lysis
of β60-74Cit peptide-specific B cells
Purified B cells of RA patients and from healthy controls
were incubated with fluorescein-loaded bifunctional
NPs. Following the treatment with active or heat-
inactivated human sera NPs, binding to live and dead B
cells was detected by flow cytometry. The binding of
fluorescein-loaded NPs was detected in FL1, while cells
stained with the dead cell indicator To-Pro-3 were spotted
in FL4. The small B-cell subset in RA samples showing
double staining in the presence of active complement rep-
resents the β60-74Cit-specific B cells killed by the bifunc-
tional NPs. This population was only detected in anti-Cit
fibrin β-positive RA patients and was completely absent in
healthy individuals (Fig. 5a). The number of dead cells
was significantly lower in samples treated with heat-
inactivated as compared with active sera, indicating the
complement-dependent lysis of β60-74Cit-specific B cells
(Fig. 5b).
Discussion
We report here for the first time that the fibrin β60-
74Cit peptide-specific B cells from RA patients can be
specifically deleted in vitro by a bifunctional NP-based
construct, where the β60-74Cit epitope and a HIV-1
gp120233–247 derivative peptide activating complement
were covalently linked to NPs. Controlled clinical trials
have shown that B-cell depletion therapies such as ritux-
imab led to significant benefit for RA patients, indicating
that B cells have a crucial role in the disease etiology
[30–32, 34]. Although rituximab therapy only moder-
ately affects pre-existing antibody titers, the patients are
transiently immunosuppressed and have an increased
risk of infection [34–36]. Therapies based on specific
targeting and elimination of the autoantigen (e.g., citrul-
linated protein/peptide)-specific B cells would therefore
be most advantageous.
Circulating plasma blasts/cells from RA patients se-
crete ACPA in vitro, indicating that in addition to the
memory B-cell pool specific for citrullinated proteins/
peptides there is an ongoing immune response in ACPA
seropositive patients [39, 40]. Previous experiments re-
vealed that the three Cit-containing fibrin β60–74 peptide
represents the major ACPA epitope on the β chain of fi-
brin [11]. In our cohort 52 % of RA patients have shown
serum antibody positivity with an average ELISA ratio
around 10. Based on these data we selected patients with
high antibody level for the cellular and functional assays.
Next, purified B cells from these selected patients were
examined for β60-74Cit peptide positivity and for in vitro
antibody production. Since the number of peptide-
positive cells was expected to be low [40], and serum
antibodies have low affinity to the citrullinated pep-
tides [50, 51], the detection of peptide-specific cells is
difficult. Therefore we stimulated B cells via TLR9,
promoting proliferation independently from B-cell re-
ceptor and increasing the frequency of memory cells
[49]. To increase the avidity of peptide binding to B
cells and to improve detection of binding, we applied
fluorescent microspheres coated with neutravidin and
the biotinylated β60-74Cit peptide. Under these con-
ditions we detected 2–3 % specific binding, indicating
that β60-74Cit peptide-positive B cells are present in
the circulation of RA patients and thus could be tar-
geted by this peptide.
We also measured antibody secretion in the superna-
tants of ex vivo activated B cells, and in agreement with
earlier results [39, 40] we found that even nonstimulated
B cells from RA patients but not from healthy individ-
uals secrete β60-74Cit peptide-specific antibodies that
were significantly elevated due to stimulation with CpG.
Interestingly, a low level of antibody production was ob-
served with the control peptide (β60-74Arg) as well but
that was not influenced by stimulation and was signifi-
cantly lower in each sample as compared with the citrul-
linated peptide samples.
Depleting activity of antibody therapeutics is based on
Fc-dependent effector functions such as antibody-
dependent cytotoxicity and complement activating cap-
acity inducing complement-dependent lysis [41, 42]. In
order to combine the β60-74Cit peptide mimicking the
autoantigen with an entity destroying the targeted B cells
by complement-dependent lysis, we applied the HIV-1
gp120 derivative peptide CNNK. This peptide stimulated
the classical pathway of complement activation and initi-
ated the deposition of C3, C4, and C9 to the peptide-
coated surfaces, at a degree comparable with IgG.
For targeted delivery of the effector, complement acti-
vating peptide and to increase the binding avidity of β60-
74Cit peptide to B cells, we utilized biodegradable PLGA
NPs that are not immunogenic, are nontoxic for cells, and
are applicable under in vivo conditions [47]. NPs covered
both with the effector peptide CNNQK and the targeting
epitope peptide β60-74Cit were able to initiate the forma-
tion of soluble C5b-9 complex in human serum corre-
sponding to the membrane attack complex, suggesting
that the bifunctional NPs could induce cell lysis.
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We postulated that these bifunctional NPs would in-
deed destroy B cells specific for the targeting compound,
β60-74Cit peptide. Experiments testing the cytotoxic ef-
fect have shown that a small population (0.7–0.9 %) of B
cells from RA patients having high serum antibody level
bound NPs and a subset of these cells was killed in the
presence of active complement.
Finally, as a proof of concept, the effect of bifunctional
NPs was tested on ex vivo β60-74Cit peptide-specific
antibody secretion. Depending on the serum concentra-
tion and the presence of active complement, the treat-
ment of stimulated PBMCs with bifunctional NPs
significantly reduced the number of β60-74Cit peptide-
specific IgG-producing plasma cells in cultures obtained
from RA patients. The number of plasma cells synthesiz-
ing nonspecific IgG in response to CpG stimuli was not
modified significantly, demonstrating that the β60-74Cit
epitope-specific autoreactive B cells are selectively de-
pleted by the bifunctional NPs. Moreover, since this
treatment diminishes citrullinated peptide-specific auto-
antibody production in vitro, it may result in a lower rate
of autoreactive immune complex formation in seropositive
patients, thus reducing inflammation. This pilot study
only shows in vitro depletion of B cells recognizing a sin-
gle epitope of fibrin, β60-74Cit. We suppose that a mix-
ture of lytic NPs should be applied simultaneously,
targeting several different autoantigen epitope-specific B
cells. Since an autoantigen-specific depleting therapy
affects only a small subset, it should leave the rest of the B
cells unattended and enable them to respond to microbial
stimuli.
Conclusion
Taken together, the data of this pilot study demonstrate
that biodegradable NPs armed with an epitope peptide
(β60-74Cit) targeting B cells from RA patients and with an
effector peptide (CNNQK) activating complement can des-
troy autoreactive, β60-74Cit-specific B cells in vitro. These
data indicate that such constructs might be suitable for
future development of personalized autoantigen-specific
depletion therapy.
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